Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
Showing 1 - 25 of >10,000
Hemorrhagic Fever, Ebola Trial in Worldwide (Ad26.ZEBOV, MVA-BN-Filo, Placebo)
Completed
- Hemorrhagic Fever, Ebola
- Ad26.ZEBOV
- +2 more
-
BoboDioulasso, Burkina Faso
- +6 more
Feb 9, 2022
Ebola Virus Disease, Ebola, Hiv Trial in Nairobi, Masaka (Ad26.ZEBOV)
Active, not recruiting
- Ebola Virus Disease
- +2 more
- Ad26.ZEBOV
-
Nairobi, Kenya
- +1 more
Nov 26, 2021
Healthy Trial in Worldwide (Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo)
Active, not recruiting
- Healthy
- Ad26.Mos4.HIV
- +2 more
-
Birmingham, Alabama
- +52 more
Jan 17, 2023
Healthy Trial in Cuangugu, Gysenyi, Kigali (Ad26.ZEBOV, MVA-BN-Filo)
Active, not recruiting
- Healthy
- Ad26.ZEBOV
- MVA-BN-Filo
-
Cuangugu, Rwanda
- +2 more
Jan 17, 2023
Virus Diseases, Hemorrhagic Fever, Ebola, Infections Trial in Kambia (Ad26.ZEBOV, MVA-BN-Filo)
Recruiting
- Virus Diseases
- +10 more
- Ad26.ZEBOV, MVA-BN-Filo
-
Kambia, Sierra LeoneEBOVAC Kambia 1 clinic
Oct 11, 2022
Ebola Virus Disease Trial in Boende (Ad26.ZEBOV vaccine)
Completed
- Ebola Virus Disease
- Ad26.ZEBOV vaccine
-
Boende, Province De La Tshuapa, Congo, The Democratic Republic of theHôpital Général de Référence de Boende
Jan 3, 2023
Ebola Virus Disease Trial in Kambia (Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection)
Active, not recruiting
- Ebola Virus Disease
- Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
-
Kambia, Sierra LeoneEBOVAC Kambia 1 clinic
Feb 25, 2022
Ebola Virus Disease Trial in Freetown (Ad26.ZEBOV, MVA-BN-Filo, MenACWY)
Completed
- Ebola Virus Disease
- Ad26.ZEBOV
- +3 more
-
Freetown, Sierra Leone(unnamed)
Jun 22, 2022
Ebola Virus Disease Trial in Kinshasa (Ad26.ZEBOV, MVA-BN-Filo vaccine)
Active, not recruiting
- Ebola Virus Disease
- Ad26.ZEBOV, MVA-BN-Filo vaccine
-
Kinshasa, Congo, The Democratic Republic of theL'Institut National de Recherche Biomédicale RDC
Nov 15, 2021
EBOVAC-Salone Extension
Active, not recruiting
- Ebola Virus Disease
- Follow-up
- Blood sample collection
-
Rokupr, Kambia, Sierra Leone
- +1 more
Feb 25, 2022
Human Immunodeficiency Virus Trial in Boston (Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140)
Completed
- Human Immunodeficiency Virus
- Ad26.Mos4.HIV
- +3 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Feb 7, 2022
Human Immunodeficiency Virus Trial in Bangkok (Ad26.Mos.HIV, MVA-Mosaic, Placebo)
Completed
- Human Immunodeficiency Virus
- Ad26.Mos.HIV
- +2 more
-
Bangkok, Thailand(unnamed)
Dec 29, 2021
Ebola Virus Trial in Kampala (cAd3-EBO S vaccine)
Completed
- Ebola Virus
- cAd3-EBO S vaccine
-
Kampala, UgandaMakerere University-Walter Reed Project
Nov 10, 2022
Hemorrhagic Fever, Ebola Trial in Worldwide (Ad26.ZEBOV, MVA-BN-Filo, Placebo)
Completed
- Hemorrhagic Fever, Ebola
- Ad26.ZEBOV
- +2 more
-
Silver Spring, Maryland
- +6 more
Jan 27, 2022
Ebola Virus Disease Trial in Entebbe (Ad26.ZEBOV/MVA-BN-Filo)
Completed
- Ebola Virus Disease
-
Entebbe, UgandaMRC/UVRI & LSHTM Uganda Research Unit
May 10, 2021
HIV-1-infection Trial in Pathum Wan (VRC07-523LS, PGDM1400LS, N-803)
Not yet recruiting
- HIV-1-infection
- VRC07-523LS
- +7 more
-
Pathum Wan, Bangkok, Thailand
- +1 more
Mar 8, 2023
Marburg Virus Disease Trial in Silver Spring (cAd3-Marburg vaccine)
Completed
- Marburg Virus Disease
- cAd3-Marburg vaccine
-
Silver Spring, MarylandWRAIR Clinical Trials Center,
Aug 9, 2022
Ebola Virus Disease, Marburg Virus Disease Trial in Oklahoma City (cAd3-Marburg, cAd3-EBO-S)
Completed
- Ebola Virus Disease
- Marburg Virus Disease
- cAd3-Marburg
- cAd3-EBO-S
-
Oklahoma City, OklahomaOklahoma Blood Institute (OBI)
Aug 2, 2022
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
Not yet recruiting
- Covid-19 Pandemics
- Tuberculosis
- Pfizer-BioNTech COVID-19 vaccine
- +2 more
-
Mae Sot, Tak, ThailandShoklo Malaria Research Unit (SMRU)
Oct 21, 2022
Respiratory Syncytial Virus Trial in Worldwide (Ad26.RSV.preF, Placebo, Nimenrix)
Completed
- Respiratory Syncytial Virus
- Ad26.RSV.preF
- +2 more
-
Geelong, Australia
- +24 more
Nov 23, 2021
Healthy Trial in Rwanda, United States (Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140)
Completed
- Healthy
- Ad26.Mos.HIV
- +3 more
-
Birmingham, Alabama
- +9 more
Jul 5, 2022
Healthy Trial in United States (Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg)
Completed
- Healthy
- Placebo
- +8 more
-
Huntsville, Alabama
- +5 more
Aug 2, 2022
COVID-19 Trial in United States (Ad26.COV2.S, BNT162b2, mRNA-1273)
Recruiting
- COVID-19
- Ad26.COV2.S
- +4 more
-
Atlanta, Georgia
- +11 more
Aug 11, 2022